Increased tubulin acetylation accompanies reversion to stable ploidy in vincristine-resistant CCRF-CEM cells

Cancer Genetics and Cytogenetics

Volumn 87, Issue 2, 1996, Pages 117-122

  Geyp, Melissa ^a   Ireland, Christine M ^a,b   Pittman, Sally M ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TUBULIN; VINCRISTINE;

ACETYLATION; ARTICLE; CELL CYCLE S PHASE; HUMAN; HUMAN CELL; KARYOTYPING; MICROTUBULE ASSEMBLY; MITOSIS SPINDLE; PLOIDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; T CELL LEUKEMIA; CELL LINE; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; METABOLISM;

ACETYLATION; CELL LINE; DRUG RESISTANCE; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; PLOIDIES; TUBULIN; VINCRISTINE;

EID: 0029867775     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-4608(95)00235-9     Document Type: Article

References (47)

1. Pui CH, Cairoll AJ, Head D, Raimondi SC, Schuster JJ, Crist WM, Link MP, Borowitz MJ, Behm FG, Land VJ, Nash MB, Pullen DJ, Look AT (1990): Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. Blood 76:590-596.
2. Kaneko Y, Kanada N, Maseki N, Sakurai M, Tsuchida Y, Takeda T, Okabe I, Sakurai M (1987): Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47:311-318.
3. Bourhis J, De Vathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, McNally NJ, Lemerle J, Riou G, Benard J (1991): Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 51:33-36.
4. Cheng J, Haas M (1990): Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502-5509.
5. Pittman SM, Kavallaris M, Stewart BW (1993): Karyotypic analysis of CCRF-CEM and drug-resistant cell lines with stable and unstable ploidy. Cancer Genet Cytogenet 66:54-62.
6. Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Steward BW (1989): Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): Resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res 49:5281-5287.
7. Evan GI, Littlewood TD (1993): The role of c-myc in cell growth. Cur Opin Genet Dev 3:44-49.
8. Amati B and Land H (1994): Myc-Max-Mad: A transcription factor network controlling cell cycle progression, differentiation and death. Cur Opin Genet Dev 4:102-108.
9. Askew DS, Ashmun RA, Simmons BC, Cleveland JL (1991): Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922.
10. Hartwell L (1992): Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991): Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
12. Sasano H, Carleton GT, Wilkinson DS, Silverberg S, Comerford J, Hyde J (1990): Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum Pathol 21:382-391.
13. Morkve O, Halvorsen OJ, Stangeland L, Gulsvik A, Laerum OD (1992): Quantitation of biological tumor markers (p53, c-myc, Ki67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer. Int J Cancer 52:851-855.
14. Volm M, Efferth T, Mattern J (1992): Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12:11-20.
15. Sasano H, Comerford J, Wilkinson DS, Schwartz A, Garrett CT (1990): Serous papillary adenocarcinoma of the endometrium. Cancer 65:1545-1551.
16. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D (1988): P53 expression in breast cancer. Int J Cancer 41:178-183.
17. Akslen LA, Morkve O (1992): Expression of p53 protein in cutaneous melanoma. Int J Cancer 52:13-16.
18. Morkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A, Laerum OD (1993): Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 13:571-578.
19. Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SEM, Salter DM, Bird CC, Wyllie AH, Hooper ML, Clarke AR (1994): Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9:603-609.
20. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G (1990): Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 45:450-456.
21. Tamura G, Maesawa C, Suzuki Y, Satodate R, Ishida K, Saito K (1992): p53 gene mutations in esophageal cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 83:559-562.
22. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G (1992): Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch [A] 421:291-295.
23. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K (1993): Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67:589-593.
24. Kros JM, Godschalk JJCJ, Krishnadath KK and Van Eden CG (1993): Expression of p53 in oligodendrogliomas. J Pathol 171:285-290.
25. Sun XF, Carstensen JM, Stal O, Zhang H, Nilsson E, Sjodahl R, Nordenskjold B (1993): Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch [A] 423:443-448.
26. Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S (1994): p53 overexpression in human esophageal carcinoma: A correlation with tumour DNA ploidy and two parameter flow cytometric study. Anticancer Res 14:1305-1312.
27. Toffoli G, Doglioni C, Cernigoi C, Frustaci S, Perin T, Canal B, Boiocchi M (1994): P53 overexpression in human soft tissue sarcomas: Relation to biological aggressiveness. Ann Oncol 5:167-172.
28. Van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG (1994): p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression. J Nat Cancer Inst 86:1011-1017.
29. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A (1994): Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73:2380-2385.
30. Taylor IW, Hodson PJ (1984): Cell cycle regulation by environmental pH. J Cell Physiol 121:517-525.
31. Houghton JA, Houghton PJ, Hazelton BJ, Douglass EC (1985): In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45:2706-2712.
32. Pain J, Sirotnak FM, Barrueco JR, Yang C-H, Biedler JL (1988): Altered molecular properties of tubulin in a multidrug-resistant variant of Chinese hamster cells selected for resistance to Vinca alkaloids. J Cell Physiol 136:341-347.
33. R15 β-tubulin mutations in Chlamydomonas reinhardtii confer altered sensitivities to microtubule inhibitors and herbicides by enhancing microtubule stability. J Cell Biol 113:605-614.
34. James SW, Silflow CD, Stroom P, Lefebvre PA (1993): A mutation in the α1-tubulin gene of Chlamydomonas reinhardtii confers resistance to anti-microtubule herbicides. J Cell Sci 106:209-218.
35. Schulze E, Asai DJ, Bulinski JC, Kirschner M (1987): Posttranslational modification and microtubule stability. J Cell Biol 105:2167-2177.
36. Piperno G, LeDizet M, Chang X-J (1987): Microtubules containing acetylated α-tubulin in mammalian cells in culture. J Cell Biol 104:289-302.
37. Gundersen GG, Khawaja S, Bulinski JC (1987): Postpolymerization detryosination of α-tubulin: A mechanism for subcellular differentiation of microtubules. J Cell Biol 105:251-264.
38. Kreis TE (1987): Microtubules containing detyrosinated tubulin are less dynamic. EMBO J 6:2597-2606.
39. Webster DR, Borisy GG (1989): Microtubules are acetylated in domains that turn over slowly. J Cell Sci 92:57-65.
40. Takemura R, Okabe S, Umeyama T, Kanai Y, Cowan NJ, Hirokawa N (1992): Increased microtubule stability and alpha tubulin acetylation in cells transfected with microtubule-associated proteins MAP1B, MAP2 or tau. J Cell Sci 103:953-964.
41. Khawaja S, Gundersen GG, Bulinski JC (1988): Enhanced stability of microtubules enriched in detyrosinated tubulin is not a direct function of detyrosination level. J Cell Biol 106:141-149.
42. Webster DR, Wehland J, Weber K, Borisy GG (1990): Detyrosination of alpha tubulin does not stabilize microtubules in vivo. J Cell Biol 111:113-122.
43. Banerjee A, Roach MC, Trcka P, Luduena RF (1990): Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of β-tubulin. J Biol Chem 265:1794-1799.
44. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE (1965): Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-529.
45. Pollice AA, McCoy JP, Shackney SE, Smith AC, Argarwal J, Burholt DR, Janocko LE, Hornicek FJ, Singh SC, Hartsock RJ (1992): Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry 13:432-444.
46. Geyp M, Ireland CM, Pittman SM (1996): Resistance to apoptotic cell death in a drug resistance T-cell leukemia line. Leukemia (in press).
47. Pittman SM, Strickland D, Ireland CM (1994): Polymerization of tubulin in apoptotic cells is not cell cycle dependent. Exp Cell Res 215:263-272.